131 related articles for article (PubMed ID: 8510328)
1. [Growth characteristics of a human myeloma cell line transfected with IL-6 cDNA].
Takahashi T; Okuno Y; Ohsugi Y
Rinsho Ketsueki; 1993 Apr; 34(4):423-6. PubMed ID: 8510328
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H
Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457
[TBL] [Abstract][Full Text] [Related]
3. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of multiple myeloma cell growth].
Simizu S; Konda S
Rinsho Ketsueki; 1993 Apr; 34(4):418-22. PubMed ID: 8510327
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-6 on the growth of human lung cancer cell line.
Fu J; Zheng J; Fang W; Wu B
Chin Med J (Engl); 1998 Mar; 111(3):265-8. PubMed ID: 10374431
[TBL] [Abstract][Full Text] [Related]
7. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
8. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
[TBL] [Abstract][Full Text] [Related]
9. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.
Westendorf JJ; Ahmann GJ; Armitage RJ; Spriggs MK; Lust JA; Greipp PR; Katzmann JA; Jelinek DF
J Immunol; 1994 Jan; 152(1):117-28. PubMed ID: 7504707
[TBL] [Abstract][Full Text] [Related]
10. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
Jourdan M; Zhang XG; Portier M; Boiron JM; Bataille R; Klein B
J Immunol; 1991 Dec; 147(12):4402-7. PubMed ID: 1753108
[TBL] [Abstract][Full Text] [Related]
11. Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells.
Lu C; Sheehan C; Rak JW; Chambers CA; Hozumi N; Kerbel RS
Clin Cancer Res; 1996 Aug; 2(8):1417-25. PubMed ID: 9816316
[TBL] [Abstract][Full Text] [Related]
12. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
13. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
14. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma.
Portier M; Rajzbaum G; Zhang XG; Attal M; Rusalen C; Wijdenes J; Mannoni P; Maraninchi D; Piechaczyk M; Bataille R
Eur J Immunol; 1991 Jul; 21(7):1759-62. PubMed ID: 2060582
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice.
Tartour E; Fossiez F; Joyeux I; Galinha A; Gey A; Claret E; Sastre-Garau X; Couturier J; Mosseri V; Vives V; Banchereau J; Fridman WH; Wijdenes J; Lebecque S; Sautès-Fridman C
Cancer Res; 1999 Aug; 59(15):3698-704. PubMed ID: 10446984
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.
Levy Y; Tsapis A; Brouet JC
J Clin Invest; 1991 Aug; 88(2):696-9. PubMed ID: 1864979
[TBL] [Abstract][Full Text] [Related]
17. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
[TBL] [Abstract][Full Text] [Related]
18. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
19. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.
Billadeau D; Jelinek DF; Shah N; LeBien TW; Van Ness B
Cancer Res; 1995 Aug; 55(16):3640-6. PubMed ID: 7627974
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]